Fig. 2From: Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis CComparison of non-structural protein 5A resistance-associated variants (RAVs) prevalence based on previous interferon-based treatment experience (a) and liver cirrhosis (LC) (b) in patients with chronic hepatitis C genotype 1bBack to article page